

**IN THE CLAIMS:**

Amend the claims as follows:

1. (Original) A method for inhibiting KDR/FIk-1 signal transduction, which comprises using a substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/FIk-1.

2. (Original) A method for inhibiting cell growth, which comprises using a substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/FIk-1.

Claims 3-9 (Canceled).

10. (Currently Amended) The method according to any one of claims 1 to 9 to 2, wherein the signal transduction molecule is phospholipase C- $\gamma$  (PLC- $\gamma$ ).

11. (Currently Amended) The method according to any one of claims 1 to 9 to 2, wherein the substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/FIk-1 is an antibody which specifically recognizes 1175-tyrosine phosphorylated KDR/FIk-1.

12. (Original) The method according to claim 11, wherein the antibody which specifically recognizes 1175-tyrosine phosphorylated KDR/FIk-1 is an antibody which

SHIBUYA, et al.  
Appl. No. Unassigned  
Div. of SN 09/969,037  
January 26, 2004

binds to the 1175-tyrosine phosphorylated KDR/FIk-1 and inhibits phosphorylation of PLC- $\gamma$ .

13. (Currently Amended) The method according to claim 11-~~or 12~~, wherein the antibody is a monoclonal antibody or the antibody fragment thereof.

Claims 14-41 (Canceled).

42. (new) The method according to claim 12, wherein the antibody is a monoclonal antibody or the antibody fragment thereof.